Mirum Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Mirum Pharmaceuticals Inc MIRM.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -52 cents. The mean expectation of nine analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -50 cents to -21 cents per share.

• Revenue rose 64.1% to $127.79 million from a year ago; analysts expected $108.17 million.

• Mirum Pharmaceuticals Inc's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $5.86 million.

• Mirum Pharmaceuticals Inc shares had risen by 1.9% this quarter and gained 25.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.6% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $73.00, about 29% above its last closing price of $51.84

This summary was machine generated from LSEG data August 6 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)